-
Controlling blood glucose early in the course of type 1 diabetes yields huge dividends, preserving kidney function for decades. The new finding from a study funded by the National Institutes of Health was published online in the New England Journal of Medicine Nov. 12 to coincide with presentation at a scientific meeting.
National Institutes of Health (Diabetology) - Tue, 15 November 2011
http://www.nih.gov
-
In type 2 diabetes, you can use incretin-mimetic drugs to stimulate insulin secretion and mitigate glucagone release, slowing gastric emptying at the same time. Among these ones, exenatide (an agonist of glucagone-like peptide-1 ( GLP-1) receptors) needs one-two daily administrations, so a long-acting formulation is being studied, with a weekly administration. Sitagliptin (an inhibitor of dipeptidyl-peptidase-4) is based on a similar mechanism of action, slowing the degradation of endogenous GLP-1. This kind of drugs can represent therapeutical alternatives to sulfonylurea or to thiazolidinediones, when metformin alone is not capable to control diabetes.
MedNews (Diabetology) - Mon, 7 November 2011
http://mn.medsurfnews.com/
-
source of the diabetic nerve pain and degeneration begins with a special fusion of bone marrow and nerve cells that lead to nerve death and dysfunction – proving that diabetes is indeed "bad to the bone," said researchers from Baylor College of Medicine in two recent reports.
Baylor College of Medicine (Diabetology) - Wed, 19 October 2011
http://www.bcm.edu
-
In diabetic patients, the highest pressure limit has been established in a value under 130/80 mmHg, but can the presence of a coronary artery disease induce to different recommendations? Some researchers have analyzed the data collected with the INVEST trial (a randomized trial on people with hypertension and coronary artery disease, treated with beta-blockers or Ca-antagonists). Some previous conclusions had not recommended a too aggressive treatment of hypertension, verifying that in these patients it would have implied an excess in cardiovascular events.
MedNews (Diabetology) - Mon, 12 September 2011
http://mn.medsurfnews.com/
-
It is well known that obesity and fat excess are factors predisposing to diabetes mellitus, but how can we quantify this association? A wide cohort trial has been used to monitor about 4,000 elderly (age ≥ 65) for a duration of averagely 12 years. During that period, 339 new cases of diabetes have been identified. Relating BMI with diabetes onset, it was seen that for subjects belonging to the higher quintile (in the division according to obesity), the risk to develop diabetes was 4 to 5 times higher than in subjects belonging to the lower quintile.
MedNews (Diabetology) - Mon, 12 September 2011
http://mn.medsurfnews.com/
-
In the therapeutic equipment of type-2 diabetics, exenatide has recently appeared, an agonist of glucagone-like peptide (GLP-1) receptors; its mechanism of action lies in the stimulus of glucose-dependent insulin secretion, in reducing glucagone secretion and in slowing down the period of gastric emptying, with the consequent decrease of food intake. The FDA has approved its daily formulation (two injections a day), but it was shown that a single weekly injection is more effective in reducing HbA1c and in obtaining weight loss.
MedNews (Diabetology) - Mon, 5 September 2011
http://mn.medsurfnews.com/
-
Whole rice contains external bran and germ, elements which are put apart in white rice processing; this one has a higher glycemic index than the whole one. In the USA, there is an average annual consumption of rice of about 9.5 kg per person, with a prevalence of husked rice (70%). Some researcher at Harvard have collected the data from three cohort prospective trials to assess the possible difference in the risk to develop type 2 diabetes according to the kind of used rice.
MedNews (Diabetology) - Mon, 29 August 2011
http://mn.medsurfnews.com/
-
Staying physically active reduces the risk of developing type 2 diabetes. Yet women at high risk for the disease are less likely than other women to stay active enough to lower their risk, according to a recent federal report.
Centers for Disease Control and Prevention (CDC) (Diabetology) - Tue, 19 July 2011
http://www.cdc.gov/
-
In final draft guidance issued today (15 July), NICE has not recommended ranibizumab (Lucentis, Novartis) for the treatment of diabetic macular oedema (DMO). The independent Appraisal Committee considered that the manufacturer's model underestimated the incremental cost-effectiveness ratio (ICER) for ranibizumab monotherapy compared with the current standard treatment for people with DMO, laser photocoagulation, which uses heat to seal ocular blood vessels.
National Institute for Health and Clinical Excellence (Diabetology) - Mon, 18 July 2011
http://www.nice.org.uk
-
Rheumatoid arthritis (RA) and psoriasis have been linked with insulin resistance and diabetes mellitus (DM). Prior investigations suggest that systemic immunosuppressive drugs may improve insulin resistance and reduce the risk of DM.
Journal of the American Medical Association (Diabetology) - Wed, 22 June 2011
http://jama.ama-assn.org/